Table 1 Baseline characteristics
From: Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus
Age (years) | 53.2 ± 2.6 |
Gender (male/female) | 13/2 |
Body mass index (kg/m2) | 27.1 ± 1.5 |
Duration of diabetes (years) | 7.0 ± 1.0 |
Diabetes complication | Â |
 Neuropathy | 9 (60.0) |
 Retinopathy | 2 (13.3) |
 Nephropathy | 0 (0.0) |
Diabetes therapy | Â |
 Diet only | 2 (13.3) |
 Sulfonylurea | 12 (80.0) |
 Pioglitazone | 0 (0.0) |
 Metformin | 3 (20.0) |
Other treatments | Â |
 Lipid-lowering drugs | 4 (26.7) |
 Antihypertensive drugs | 5 (48.8) |
Current smokers | 9 (60.0) |
Cardiovascular disease | 2 (13.3) |
Systolic blood pressure (mmHg) | 127.4 ± 4.3 |
Diastolic blood pressure (mmHg) | 80.6 ± 3.3 |
LDL-C (mg/dL) | 119.5 ± 9.3 |
HDL-C (mg/dL) | 45.7 ± 3.5 |
Triglycerides (mg/dL) | 153.0 ± 9.5 |
HbA1c (%) | 9.5 ± 0.4 |
Fasting plasma glucose (mg/dL) | 153.0 ± 9.5 |
Immunoreactive insulin (μU/mL) | 7.4 ± 1.1 |
HOMA-IR | 2.8 ± 0.5 |
HOMA-β | 32.2 ± 5.7 |
C-peptide in urine (μg/day) | 101.2 ± 18.8 |
L_RHI | 0.54 ± 0.04 |